Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

Delamanid approved for use in the European Union

otsuka

The European Commission has approved delaminid (Deltyba) for use in patients suffering from MDR-TB.

TB Alliance launches landmark Phase 3 clinical trial aimed at shortening duration of TB treatment

TBAlliance

TB Alliance announces STAND, a Phase 3 Clinical Trial aimed at shortening the duration of treatment for drug-sensitive and MDR-TB.

TB R&D Update: Tuberculosis drug, SQ109, targets multiple enzymes and could treat other diseases while preventing resistance

SQ109

The drug SQ109, developed by Sequella for the treatment of tuberculosis, blocks key biochemical pathways in bacteria, fungi, and parasites. Its range and ability to inhibit multiple targets, makes SQ109 an attractive broad-based antimicrobial compound that also reduces the likelihood of resistance developing in bugs.

27 Mar 2014
by Working Group

Posted in Announcements, TB News, TB Pediatrics, Uncategorized

TB Alliance makes series of announcements regarding new initiatives to combat childhood TB

TBAlliance

TB Alliance, an international non-profit whose mission is to develop better and more affordable drugs against tuberculosis, made three announcements on World TB Day demonstrating their commitment to combating childhood TB.

TB R&D Update: Researchers at EPFL create organization to help bring promising new antibiotic, ‘PBTZ169’, to market

PBTZ169

Researchers at EPFL and the Bach Institute in Moscow have discovered an antibiotic effective against sensitive and MDR-tuberculosis. With support from EPFL, the researchers have created Innovative Medicines for Tuberculosis (iM4TB), an organization to help usher the new antibiotic to market.

Sirturo (bedaquiline) approved for conditional use in European Union to treat MDR-TB in adults

Sirturo

The European Medicines Agency has recently approved Sirturo for conditional use in the European Union. A link to the press release is included.

TB R&D Update: Semisynthetic antibiotic effective against sensitive and drug resistant tuberculosis in vitro

St Judes

This week we highlight a study by Richard E. Lee et al showing that semisynthetic antibiotic, spectinamides, is effective against drug sensitive and resistant tuberculosis. Additional links related to this study and general TB R&D are included.

26 Nov 2013

EMA Reverses Opinion on Delamanid for MDR-TB

otsuka

A European Union panel has recommended regulatory approval of a tuberculosis drug that would become only the second major new antibiotic against the deadly disease in more than 40 years.

25 Oct 2013

WHO Global TB Report 2013: Slow decline in Disease Burden, New Tools Needed to Reach Goals

GTBR13_cover M inhouse

This is the eighteenth global report on tuberculosis (TB) published by WHO in a series that started in 1997. It provides a comprehensive and up-to-date assessment of the TB epidemic and progress made to date. Additional links to news coverage of the report are included

10 Sep 2013
by Working Group

Posted in TB Drug Development, TB News

Fighting Tuberculosis With FDA Approved Hypertensive Drug Verapamil

ShashankGupta_Lab_Photo on

In a significant finding for millions of TB patients, researchers have recently shown that adjunct chemotherapy with verapamil can accelerate tuberculosis treatment in mouse model.